SAN DIEGO, May 2, 2012 /PRNewswire/ -- Synteract, Inc., a full-service contract research organization (CRO), and Rempex Pharmaceuticals, a biopharmaceutical company developing new therapies to combat the growing issue of antibiotic resistance, have partnered for the third annual Great Strides fundraising walk to benefit the Cystic Fibrosis (CF) Foundation through participation and donations. Synteract and Rempex (on behalf of Aptalis Pharma) are also working together on clinical trials to combat the disease.
(Logo: http://photos.prnewswire.com/prnh/20111108/MM02925LOGO)
“Great Strides: Taking Steps To Cure Cystic Fibrosis” is the largest fundraising event held by the Cystic Fibrosis Foundation to raise money for CF research and care. Synteract and Rempex employees will participate in this walk-a-thon on Sunday, May 6 at the Powerhouse Park in Del Mar to help fund a cure for the disease. The three-mile walk will bring co-workers, friends and families together in support of the work of the Cystic Fibrosis Foundation. Employees from both teams increased their fundraising efforts by hosting educational events and internal activities to raise additional donations. This is the second year the two companies have participated in the walk.
“Synteract and Rempex are pleased to be able to help the Cystic Fibrosis Foundation in its fundraising efforts and education of the community about such debilitating diseases,” said Stewart Bieler, Chief Operating Officer at Synteract. “With the support of our team walkers, we are participating in the foundation’s efforts to fight Cystic Fibrosis and help find a cure.”
CF is an inherited chronic disease that affects the lungs and digestive systems of about 30,000 children and adults in the United States. There are about 1,000 new cases diagnosed with the disease each year. The Cystic Fibrosis Foundation has been fighting to find a cure and welcomes supporters like Synteract and Rempex.
Those who are interested in donating to the foundation or participating in the walk can contact Synteract representative Kathy Kaplan at 760-268-8200 or the Cystic Fibrosis Foundation at www.cff.org.
About Synteract (www.synteract.com)
Synteract is a full-service contract research organization with a successful 17-year track record supporting biotechnology, medical device and pharmaceutical companies in all phases of clinical development. With its “Shared Work Shared Vision” philosophy Synteract provides customized Phase I through IV services collaboratively and cost effectively to ensure on-time delivery of quality data so clients get to decision points faster. Headquartered in California, with offices in North Carolina and the Czech Republic, Synteract delivers trials internationally, offering expertise across multiple therapeutic areas including notable depth in oncology, CNS, cardiovascular, respiratory and ophthalmology.
CONTACT:
Antonia Genov
Clearpoint Agency, for Synteract
antonia@clearpointagency.com
760-230-2424
SOURCE Synteract, Inc.
